Boan Biotech announced that it has signed a licensing agreement for commercializing its self-developed Denosumab Injection (BA6101 and BA1102) in the Brazilian market with a strategic partner.Under th...
Boan Biotech announced that the first patient has been dosed in the Phase 1 clinical trial of BA1302, a novel CD228-directed antibody drug conjugate (ADC),which is the only CD228 ADC undergoing clinic...
Shanghai, November 11, 2024 -Luye Pharma Group today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved its Investigational...
Strong net profit growth: 201%Five new drugs approved for marketingShanghai, August 28, 2024 -- Luye Pharma Group today announced its 2024 half-year results and latest developments.During the reportin...
YANTAI, China, Aug. 27, 2024-- Boan Biotech (6955.HK) today announced its 2024 half-year results and latest developments.During the reporting period, the company's total revenue was RMB 363 millio...
PRINCETON, N.J., July 28, 2024 – Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of innovative medications, today annou...
Shanghai, July 4, 2024 – Luye Pharma Group announced that its Mimeixin (oxycodone hydrochloride and naloxone hydrochloride sustained-release tablets) was approved for marketing by China's Na...
The world’s first long-acting microsphere formulation for treating Parkinson’s disease is another CNS product of the company approved in the fast track processJune 20, 2024 – Luye Ph...
June 11, 2024 - Luye Pharma Group today announced that its second-generation long-acting injectable (LAI) antipsychotic Meibirui (Paliperidone Palmitate Injection) has been approved for marketing by C...
June 6, 2024 – Luye Pharma Group announced that its partner Towa Pharmaceutical Co., Ltd. (Towa) has filed a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Ja...
TOP